Oriol Mirallas: PEACE-3 – Enzalutamide + Radium-223 vs Enzalutamide alone
Oriol Mirallas shared a post on X:
”Presidential Session at ESMO.
PEACE-3: Enzalutamide (Enza) + Radium-223 (Ra223) vs Enzalutamide alone. Presented by Silke Gillessen.
- Median progression-free survival (mPFS): 19.4 months vs 16.4 months, HR 0.69.
- Time to treatment (TTT) HR: 0.57.
Grade 3 toxicity: 28% in combination therapy vs 19% with Enzalutamide alone.
Discussed by Karim Fizazi.”
Source: Oriol Mirallas/X
Oriol Mirallas is a Medical Oncologist at the Phase I Unit at Vall Hebron Institute of Oncology (VHIO) with a focus on translational and clinical cancer research. He is currently pursuing a PhD on resistance mechanisms to new drugs, using liquid biopsy analysis.
Silke Gillessen is the Medical and Scientific Director of the Oncology Institute of Southern Switzerland and a Full Professor at University of Italian Switzerland. Her expertise focuses on genitourinary (GU) cancers.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023